Anixa Biosciences price target lowered to $7 from $12 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Anixa Biosciences to $7 from $12 and keeps a Buy rating on the shares following the fiscal Q2 report. The analyst believes the company may have an operational runway of over two years.